


Correction to “Differential Activation and Modulation of the Glucagon-Like Peptide-1 Receptor by Small Molecular Ligands”

In the above article [Wootten, D, Savage EE, Willard FS, Bueno AB, Sloop KW, Christopoulos A, and Sexton PM (2013) *Mol Pharmacol* **83**:822–834], the structure drawing of TT15 in Fig. 1 is wrong. The structure should be as represented below. The name of the compound in the abbreviations on pages 822 and 823 and in Tables 1, 2, and 4 is also incorrect; it should be TT15, (2*S*)-2-[[[(8*S*)-7-benzoyl-3-[4-[(3,4-dichlorophenyl)methoxy]phenyl]-2-oxo-1,6,8,9-tetrahydropyrido[4,3-*g*][1,4]benzoxazine-8-carbonyl]amino]-3-[4-(4-cyanophenyl)phenyl]propanoic acid (IUPAC name), as indicated in the supplemental material. Intermediate 5 of the synthesis of TT15 (see supplemental material) corresponds to “intermediate A” in Mjalli, A. M. M. US Patent 7, 727, 983 B2 “Oxadiazanthracene compounds for the treatment of diabetes,” Granted patent, Editor, TransTech Pharma.



TT15 (Isomer 1)

The HTML and PDF versions of the article have been corrected.

The authors regret this error and any inconvenience it may have caused.